90 related articles for article (PubMed ID: 12496431)
1. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
[TBL] [Abstract][Full Text] [Related]
2. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
Beignon AS; Briand JP; Muller S; Partidos CD
Immunology; 2001 Mar; 102(3):344-51. PubMed ID: 11298834
[TBL] [Abstract][Full Text] [Related]
3. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.
Richards CM; Aman AT; Hirst TR; Hill TJ; Williams NA
J Virol; 2001 Feb; 75(4):1664-71. PubMed ID: 11160664
[TBL] [Abstract][Full Text] [Related]
4. T helper cell responses in adult diarrheal patients following natural infection with enterotoxigenic
Akhtar M; Basher SR; Nizam NN; Hossain L; Bhuiyan TR; Qadri F; Lundgren A
Front Immunol; 2023; 14():1220130. PubMed ID: 37809062
[TBL] [Abstract][Full Text] [Related]
5. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates.
VanCott JL; Prada AE; McNeal MM; Stone SC; Basu M; Huffer B; Smiley KL; Shao M; Bean JA; Clements JD; Choi AH; Ward RL
J Virol; 2006 May; 80(10):4949-61. PubMed ID: 16641286
[TBL] [Abstract][Full Text] [Related]
6. Application of phosphorylcholine derivative as mucosal adjuvant enhancing mucosal immune responses in the upper respiratory tract.
Jimura T; Kurono Y; Hirano T; Kawabata M; Yamashita M
Auris Nasus Larynx; 2024 Feb; 51(1):221-229. PubMed ID: 37532644
[TBL] [Abstract][Full Text] [Related]
7. LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (μMT) mice.
Valli E; Harriett AJ; Nowakowska MK; Baudier RL; Provosty WB; McSween Z; Lawson LB; Nakanishi Y; Norton EB
Sci Rep; 2019 Oct; 9(1):15128. PubMed ID: 31641151
[TBL] [Abstract][Full Text] [Related]
8. Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization.
Imai Y; Nagai R; Ono Y; Ishikawa T; Nakagami H; Tanikawa T; Kurohane K
Infect Immun; 2004 Feb; 72(2):889-95. PubMed ID: 14742533
[TBL] [Abstract][Full Text] [Related]
9. Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein.
Gockel CM; Russell MW
Immunology; 2005 Dec; 116(4):477-86. PubMed ID: 16313361
[TBL] [Abstract][Full Text] [Related]
10. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.
Scharton-Kersten T; Yu Jm; Vassell R; O'Hagan D; Alving CR; Glenn GM
Infect Immun; 2000 Sep; 68(9):5306-13. PubMed ID: 10948159
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.
Tinker JK; Yan J; Knippel RJ; Panayiotou P; Cornell KA
Toxins (Basel); 2014 Apr; 6(4):1397-418. PubMed ID: 24759174
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA.
Wakabayashi A; Shimizu M; Shinya E; Takahashi H
Cell Death Dis; 2018 May; 9(6):631. PubMed ID: 29795370
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers.
Banerjee S; Medina-Fatimi A; Nichols R; Tendler D; Michetti M; Simon J; Kelly CP; Monath TP; Michetti P
Gut; 2002 Nov; 51(5):634-40. PubMed ID: 12377799
[TBL] [Abstract][Full Text] [Related]
14. Polyclonal Treg cells enhance the activity of a mucosal adjuvant.
Vendetti S; Davidson TS; Veglia F; Riccomi A; Negri DR; Lindstedt R; Pasquali P; Shevach EM; De Magistris MT
Immunol Cell Biol; 2010 Oct; 88(7):698-706. PubMed ID: 20585335
[TBL] [Abstract][Full Text] [Related]
15. Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G.
Thiam F; Martino CD; Bon F; Charpilienne A; Cachia C; Poncet D; Clements JD; Basset C; Kohli E
Toxins (Basel); 2010 Aug; 2(8):2007-27. PubMed ID: 22069670
[TBL] [Abstract][Full Text] [Related]
16. Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans.
Khan S; Chatfield S; Stratford R; Bedwell J; Bentley M; Sulsh S; Giemza R; Smith S; Bongard E; Cosgrove CA; Johnson J; Dougan G; Griffin GE; Makin J; Lewis DJ
Vaccine; 2007 May; 25(21):4175-82. PubMed ID: 17412462
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.
Davtyan H; Ghochikyan A; Hovakimyan A; Petrushina I; Yu J; Flyer D; Madsen PJ; Pedersen LO; Cribbs DH; Agadjanyan MG
J Neuroimmunol; 2014 Mar; 268(1-2):50-7. PubMed ID: 24507620
[TBL] [Abstract][Full Text] [Related]
18. Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin.
Kim D; Kim YG; Seo SU; Kim DJ; Kamada N; Prescott D; Chamaillard M; Philpott DJ; Rosenstiel P; Inohara N; Núñez G
Nat Med; 2016 May; 22(5):524-30. PubMed ID: 27064448
[TBL] [Abstract][Full Text] [Related]
19. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.
Beignon AS; Briand JP; Muller S; Partidos CD
Immunology; 2002 Feb; 105(2):204-12. PubMed ID: 11872096
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization.
Barackman JD; Ott G; Pine S; O'Hagan DT
Clin Diagn Lab Immunol; 2001 May; 8(3):652-7. PubMed ID: 11329476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
